MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.
This release has been authorized by the directors of Immuron Limited.
| COMPANY CONTACT:
Dr Jerry Kanellos, Ph.D. |
US INVESTOR CONTACT
Dave Gentry, CEO |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- In a world increasingly driven by artificial intelligence and complex…
PALO ALTO, Calif., Jan. 14, 2025 /PRNewswire/ -- A news report from Business Next Media…
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- The Sunhak Peace Prize Committee, chaired by José…
SANTA CLARA, Calif., Jan. 14, 2025 /PRNewswire/ -- DeepSight Technology, a leading innovator in medical device…
HONG KONG / ACCESSWIRE / January 14, 2025 / Innovative supply chain management service provider…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical…